US Markets
PFE

Pfizer eyes emergency use approval for vaccine in November

Credit: REUTERS/Carlo Allegri

Pfizer Inc said on Friday it could apply for U.S. emergency use of its COVID-19 vaccine candidate being developed along with Germany's BioNTech SE as soon as a safety milestone is achieved in the third week of November.

Adds details from Pfizer's letter on its website

Oct 16 (Reuters) - Pfizer Inc PFE.N said on Friday it could apply for U.S. emergency use of its COVID-19 vaccine candidate being developed along with Germany's BioNTech SE 22UAy.F as soon as a safety milestone is achieved in the third week of November.

The U.S. Food and Drug Administration has said it wants at least two months of safety data before authorizing emergency use of any experimental coronavirus vaccine.

Based on current trial enrollment and dosing pace, Pfizer expects to have that safety data in the third week of November, Chief Executive Officer Albert Bourla said in a statement.

Pfizer had said previously that it expected late-stage trial data in October. (https://bit.ly/31bWdpP)

(Reporting by Manojna Maddipatla and Manas Mishra in Bengaluru Editing by Saumyadeb Chakrabarty)

((manojna.kalyani@thomsonreuters.com; +91 8061822700;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PFE

Latest US Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More